Dobupal 37.5 mg Tablets
venlafaxine
Read this entire package insert carefully before starting to take this medication, as it contains important information for you.
Contents of the package andadditional information
Dobupal is an antidepressant that belongs to a group of medications called serotonin and norepinephrine reuptake inhibitors (SNRIs). This group of medications is used to treat depression and other conditions such as anxiety disorders. The exact mechanism of action of antidepressants is not fully understood, but they may help increase levels of serotonin and norepinephrine in the brain.
Dobupal is a treatment for adults with depression. Properly treating depressive disorders is important to help you feel better. If left untreated, your condition may not go away or may worsen and become more difficult to treat.
Consult your doctor or pharmacist before starting to take Dobupal:
Dobupal may cause restlessness or difficulty sitting or staying still during the first few weeks of treatment. You should consult your doctor if this occurs.
Some medications in the group to which Dobupal belongs (called ISRS/IRSN) may cause sexual dysfunction symptoms (see section 4). In some cases, these symptoms persist after stopping treatment.
Do not drink alcohol during treatment with Dobupal, as it may cause extreme fatigue and unconsciousness. Taking it with certain medications and/or alcohol may worsen the symptoms of depression and other conditions, such as anxiety disorders.
If you are depressed and/or have anxiety disorders, you may sometimes have thoughts of harming yourself or committing suicide. These thoughts may increase when starting to take antidepressants, as all these medications take time to act, usually two weeks, although sometimes more. These thoughts may also occur when your dose is reduced or during the interruption of treatment with Dobupal.
It is more likely to happen:
Immediately contact your doctor or go to the nearest hospital emergency room if you have thoughts of harming yourself or committing suicide at any time.
You may find it helpful to tell a close family member or friend that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You can also ask them to tell you if they think your depression or anxiety is worsening, or if they are concerned about changes in your behavior.
Dry mouth
Dry mouth has been reported in 10% of patients treated with venlafaxine. This may increase the risk of tooth decay (caries). Therefore, you should take care of your dental hygiene.
Diabetes
Your blood glucose levels may be altered by Dobupal. Therefore, your diabetes medication doses may need to be adjusted.
Dobupal should not be used normally in the treatment of children and adolescents under 18 years old. Additionally, you should know that in patients under 18 years old, there is a higher risk of adverse effects such as suicidal thoughts, suicidal ideation, and hostility (predominantly aggression, confrontational behavior, and irritability) when taking this type of medication. However, your doctor may prescribe this medication to patients under 18 years old when deciding what is best for the patient. If your doctor has prescribed this medication to a patient under 18 years old and you want to discuss this decision, please return to your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen in these patients under 18 years old while taking Dobupal. Furthermore, the long-term safety in relation to growth, maturation, and cognitive and behavioral development has not been demonstrated.
Inform your doctor or pharmacist if you are using or have used recently or may need to use any other medication. Your doctor must decide if you can take Dobupal with other medications.
Do not start or stop taking any medication, including those available over the counter, natural remedies, or herbal products, without checking with your doctor or pharmacist.
A potentially life-threatening state, or reactions similar to Neuroleptic Malignant Syndrome (NMS) (see section "Possible side effects") may occur with treatment with venlafaxine, particularly when taken with other medications. Examples of these medications include:
The signs and symptoms of serotonin syndrome may include a combination of the following:
Restlessness, hallucinations, loss of coordination, rapid heartbeat, increased body temperature, rapid changes in blood pressure, hyperactive reflexes, diarrhea, coma, nausea, vomiting.
In its most severe form, serotonin syndrome may resemble Neuroleptic Malignant Syndrome (NMS). The signs and symptoms of NMS may include a combination of fever, rapid heartbeat, sweating, severe muscle rigidity, confusion, increased muscle enzymes (determined by blood analysis).
Immediately inform your doctor or go to the nearest hospital emergency room if you think you are experiencing serotonin syndrome.
Inform your doctor if you are taking medications that may alter your heart rhythm.
Examples of these medications include:
The following medications may interact with Dobupal and should be used with caution. It is especially important to mention to your doctor or pharmacist if you are taking medications that contain:
Dobupal should be taken with food (see section 3 "How to take Dobupal")
Do not drink alcohol during treatment with Dobupal. Taking it with alcohol may cause extreme fatigue and unconsciousness, and worsen the symptoms of depression and other conditions, such as anxiety disorders.
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication. You should only take Dobupal after discussing the possible benefits and risks for the unborn child with your doctor.
If you take Dobupal in the final stages of pregnancy, there may be a higher risk of excessive vaginal bleeding after delivery, especially if you have a history of bleeding disorders. Your doctor or midwife should know that you are taking Dobupal so they can advise you. When taken during pregnancy, similar medications (ISRS) may increase the risk of a severe condition in newborns, called persistent pulmonary hypertension of the newborn (PPHN), causing the baby to breathe faster and turn blue. These symptoms usually start within the first 24 hours after the baby's birth. If this happens to your baby, you should immediately contact your midwife and/or doctor.
If you are taking this medication during pregnancy, in addition to breathing problems, other symptoms that your baby may have when born are feeding problems. If your baby has these symptoms when born and you are concerned, contact your doctor and/or midwife, who can advise you.
Do not drive or operate tools or machines until you know how this medication affects you.
Important information about some of the components of Dobupal
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains less than 23 mg of sodium (1mmol) per tablet; it is essentially "sodium-free".
Follow exactly the administration instructions of this medication as indicated by your doctor.In case of doubt, consult your doctor or pharmacist again.
The usual recommended initial dose is 75 mg per day in divided doses, two or three times a day. Your doctor may gradually increase the dose and if necessary, even up to a maximum daily dose of 375 mg for depression.
Take Dobupal approximately at the same time every day, either in the morning or at night.
Dobupal must be taken with food.
If you have liver or kidney problems, talk to your doctor as your dose of this medication may need to be different.
Do not stop taking this medication without consulting your doctor (see section “If you interrupt treatment with Dobupal”).
In case of overdose or accidental ingestion, contact your doctor, pharmacist or call the Toxicological Information Service, phone 91 562 04 20 indicating the medication and the amount taken.
An overdose can put your life in danger, especially with the simultaneous taking of certain medications and/or alcohol (see Taking Dobupal with other medications).
The symptoms of a possible overdose may include rapid heartbeat, changes in level of consciousness (ranging from drowsiness to coma), blurred vision, seizures or attacks, and vomiting.
If you have not taken a dose, take it as soon as you remember. However, if it is already time for your next dose, skip the missed dose and take only one dose as usual. Do not take a double dose to compensate for the missed doses. Do not take more than the daily dose of Dobupal that has been prescribed to you in a day.
Do not stop taking your treatment or reduce the dose without consulting your doctor, even if you feel better. If your doctor thinks you no longer need Dobupal, they may ask you to gradually reduce the dose before stopping treatment completely. It is known that adverse effects occur when people stop using this medication, especially when it is stopped suddenly or if the dose is reduced very quickly. Some patients may experience symptoms such as suicidal thoughts, aggression, fatigue, dizziness, lack of stability, headaches, insomnia, nightmares, dry mouth, loss of appetite, nausea, diarrhea, nervousness, agitation, confusion, ringing in the ears, tingling or, in rare cases, electric shock sensations, weakness, sweating, seizures or symptoms similar to the flu, vision problems, and increased blood pressure (which can cause headaches, dizziness, ringing in the ears, sweating, etc.).
Your doctor will advise you on how to gradually stop treatment with Dobupal. This may take several weeks or months. In some patients, the interruption may need to be produced very gradually over months or more. If you experience any of these or other symptoms that bother you, consult your doctor for advice.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
If any of the following effects occur, do not take any more Dobupal.Inform your doctor immediately, or go to the nearest hospital emergency room:
Rare (may affect up to 1 in 100 people)
Uncommon (may affect up to 1 in 1,000 people)
In its most severe form, serotonin syndrome may resemble Malignant Neuroleptic Syndrome (MNS). The signs and symptoms of MNS may include a combination of fever, rapid heartbeat, sweating, severe muscle rigidity, confusion, increased muscle enzymes (determined by blood tests).
Unknown frequency (cannot be estimated from available data)
Other side effects that you should inform your doctor are (the frequency of these side effects are included in the list below "other side effects that may occur"):
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Rare (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Unknown frequency (cannot be estimated from available data)
Dobupal may sometimes cause unwanted effects that you may not be aware of, such as increased blood pressure or abnormal heartbeat; mild changes in liver enzyme levels, sodium, or cholesterol. Less frequently, Dobupal may reduce the function of platelets in the blood, leading to an increased risk of petechiae or bleeding. Therefore, your doctor may wish to perform occasional blood tests, particularly if you have been taking Dobupal for a long time.
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicinal Products for Human Use, Website:www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging. The expiration date is the last day of the month indicated.
No special storage conditions are required.Store in a dry place.
Medications should not be disposed of through drains or in the trash.Deposit empty packaging and unused medications at the SIGRE collection pointat your pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
Composition of Dobupal 37.5 mg tablets
The active ingredient is venlafaxine. Each tablet contains 42.42 mg of venlafaxine hydrochloride equivalent to 37.5 mg of venlafaxine base.
The other components (excipients) are: lactose, microcrystalline cellulose, sodium carboxymethyl starch, magnesium stearate, yellow iron oxide (E-172), and brown iron oxide (E-172).
Appearance of Dobupal and content of the packaging
Dobupal 37.5 mg is presented in the form of tablets. The tablets are circular, biplanar, with beveled edges and salmon-colored.
Dobupal 37.5 mg is presented in packaging containing 60 tablets for oral administration.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Almirall, S.A.
General Mitre, 151
08022 – Barcelona
Responsible for manufacturing
Industrias Farmacéuticas Almirall, S.A.
Ctra. de Martorell, 41-61
08740 Sant Andreu de la Barca – Barcelona (Spain)
This medicinal product was authorized in the Member States of the EEA with the following names:
Spain: Dobupal 37.5 mg tablets
Date of the last review of this leaflet:May 2023
The detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
The average price of Dobupal 37,5 mg comprimidos in July, 2025 is around 9.59 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.